1. Introduction

Artificial Organ Development Regulation refers to the legal and regulatory framework governing the research, design, manufacture, testing, clinical use, marketing and post-market monitoring of artificial organs and technologies intended to replace, support or restore the functions of damaged human organs.

Artificial organs are increasingly important in biotechnology and medical law. Examples include:

Mechanical organs: artificial hearts, ventricular assist devices and artificial heart valves.

Artificial kidneys: haemodialysis systems and implantable or wearable renal-support devices.

Artificial lungs: extracorporeal membrane oxygenation (ECMO) systems and artificial lung devices.

Bioengineered organs: laboratory-grown tissues, tissue-engineered constructs and organs developed using human cells and biomaterials.

Hybrid organs: devices combining living cells, biological materials, electronic systems and mechanical components.

The legal challenge is that artificial organs may involve several distinct regulatory categories. A mechanical heart pump may be regulated as a medical device, whereas a construct containing living human cells may raise additional questions concerning biological products, tissue handling, clinical research, manufacturing quality and long-term patient safety.

In India, there is an important starting point: the Ministry of Health and Family Welfare expressly stated in a 2022 parliamentary response that the Transplantation of Human Organs and Tissues Act, 1994 does not regulate artificial organs as such. Artificial-organ development therefore cannot be treated as if it were governed exclusively by the conventional organ-transplantation legislation.

Press Information Bureau

+1

This explanation focuses primarily on Indian law, with relevant comparative principles and judicial precedents.

2. Meaning and scope of artificial-organ regulation

Artificial-organ regulation covers the entire lifecycle of a technology, from laboratory research to clinical implantation and eventual withdrawal from use.

Research and development

Scientific validity, laboratory safety, ethics review, cell sourcing and biomaterial testing.

Preclinical and clinical evaluation

Biocompatibility, toxicity, device reliability, clinical-trial permissions and informed consent.

Manufacturing and marketing

Product classification, licences, quality systems, sterility, performance claims and traceability.

Implantation and long-term monitoring

Clinical responsibility, adverse-event reporting, cybersecurity, recalls and patient follow-up.

The central regulatory objective is to balance innovation with the constitutional and legal interests of patients, including life, health, bodily integrity, informed choice, privacy and protection against unsafe medical interventions.

3. Legal framework governing artificial organs in India

A. Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017

The principal regulatory framework for artificial organs that qualify as medical devices is the Medical Devices Rules, 2017 under the Drugs and Cosmetics Act, 1940.

The Central Drugs Standard Control Organization (CDSCO) administers the relevant central regulatory functions. Its framework addresses device manufacture, import, clinical investigation, licensing, labelling, quality and safety.

CDSCO

+1

The precise requirements depend on the device's intended purpose, design, risk classification and applicable exemptions or special provisions.

Key regulatory issues include:

Risk classification: Devices are classified according to their intended use and associated risk. A permanently implanted, life-sustaining artificial organ may raise more serious safety concerns than a lower-risk external support device.

Manufacturing authorisation: Manufacturers must obtain the applicable manufacturing licence or comply with the relevant regulatory route.

Quality assurance: The manufacturer must demonstrate that materials, assembly, sterilisation and production controls meet applicable requirements.

Performance evidence: The device must have appropriate evidence supporting its intended performance and safety.

Post-market surveillance: Adverse events, malfunctions and other safety signals may require investigation, reporting, corrective action or recall.

The CDSCO's published guidance confirms that the Medical Devices Rules provide distinct provisions for clinical investigations, labelling, manufacture, import and sale.

CDSCO

+1

B. Clinical investigation of artificial organs

An artificial heart or implantable kidney-support system may be an investigational medical device if it has not yet obtained the required regulatory authorisation for the proposed use.

Rules 49–55 of the Medical Devices Rules, 2017 address clinical investigation, ethics review, permissions, conditions and medical management or compensation for participants injured during an investigation. The precise rule applicable depends on the product and study.

IndiaCode

+1

The principal requirements include:

Permission from the competent licensing authority where required.

Approval by the appropriate ethics committee.

A scientifically justified clinical investigation plan.

Valid informed consent from participants.

Registration of the investigation where prescribed.

Monitoring and reporting of adverse events.

Medical management and compensation where legally required.

A manufacturer should not assume that a device can be implanted in patients merely because it has performed successfully in laboratory or animal studies.

C. Transplantation of Human Organs and Tissues Act, 1994

The Transplantation of Human Organs and Tissues Act, 1994 (THOTA) regulates the removal, storage and transplantation of human organs and tissues, including safeguards against commercial dealings in them.

Its provisions address matters such as authorised removal, restrictions on transplantation, registered hospitals, tissue banks and penalties for illegal dealings.

India Code

+1

However, the distinction is essential:

A fully mechanical artificial heart is not automatically a human organ transplant under THOTA.

A laboratory-grown construct containing human cells may raise questions about the legal classification of the material and the activity involved.

The use of donated human tissue or organs as a source material may trigger additional requirements even where the final product is engineered.

Therefore, artificial-organ development requires a technology-specific regulatory assessment, rather than an assumption that every artificial organ is covered by the same transplantation law.

D. Other relevant legal frameworks

These frameworks operate alongside product-specific rules; none should be assumed to replace the applicable medical-device approval process.

4. Constitutional principles

Artificial-organ regulation is closely connected with constitutional rights and public health.

Article 21: Right to life and personal liberty

Article 21 protects life and personal liberty. In medical-technology disputes, it supports the importance of access to safe treatment, bodily autonomy and protection against arbitrary or seriously unsafe medical interventions.

It does not, by itself, automatically create a right to receive every experimental artificial organ or compel approval of an unproven device.

Article 14: Equality before the law

Article 14 is relevant where regulatory decisions are arbitrary, discriminatory or inconsistent with the governing law. For example, unexplained differential treatment of comparable applications for artificial-organ trials could raise administrative-law concerns.

Article 19(1)(g): Freedom of trade and profession

Manufacturers and medical innovators may invoke Article 19(1)(g), subject to constitutionally permissible restrictions under Article 19(6). Patient safety, evidence-based approval and manufacturing standards can justify proportionate regulation.

Public-health responsibility

Government authorities must balance technological innovation with public safety. Regulatory delay can restrict access to beneficial technology, but premature approval can expose patients to catastrophic risks. Sound regulation therefore requires transparent decisions, scientific evidence, proportionality and appropriate review mechanisms.

5. Major regulatory challenges

1. Long-term safety

Mechanical failure, blood clot formation, infection, rejection of biological materials and device degradation can cause serious injury or death. Approval must consider both immediate performance and foreseeable long-term risks.

2. Bioengineered organs

Constructs containing living cells may exhibit variability, immune responses or unexpected biological behaviour. Traditional mechanical-device testing may be insufficient on its own.

3. Manufacturing consistency

Every implant must meet validated specifications. Variations in biomaterials, cell sources, software or production methods may affect safety and clinical performance.

4. Consent and access

Patients must understand material risks, uncertainties, alternatives, maintenance requirements and the possibility of device failure. Cost and unequal access also raise questions of healthcare justice.

6. Important case laws and their legal principles

A key limitation in this field is that the following decisions establish general principles of medical consent, negligence, consumer protection and regulatory responsibility. They should not be misrepresented as judgments specifically deciding the approval of artificial organs.

1. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India.

Facts and issue: The case concerned the scope of a patient's consent to medical treatment and whether consent for one procedure authorised a materially different procedure.

Legal principle: The Court explained that valid consent must be voluntary and given by a competent person with adequate information about the nature and purpose of the procedure, its benefits, substantial risks and available alternatives.

Application to artificial organs: Before implanting an experimental artificial heart, a physician should explain the device's investigational status, foreseeable complications, uncertain long-term performance, alternative treatments and potential need for replacement or further surgery.

Consent to conventional surgery should not automatically be treated as consent to an additional experimental intervention.

2. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Court: Supreme Court of India.

Facts and issue: The case concerned criminal liability for alleged medical negligence and the standard applicable to medical professionals.

Legal principle: The Court distinguished civil negligence from criminal medical negligence and explained that criminal liability requires the applicable high threshold of negligence, rather than merely an unsuccessful treatment outcome.

Application to artificial organs: If an artificial organ fails, the failure does not automatically establish criminal negligence. The investigation must consider the circumstances, including whether the medical team acted with appropriate professional care and whether a manufacturer or other responsible party breached a relevant duty.

Civil, regulatory and criminal liability must be analysed separately.

3. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

Court: Supreme Court of India.

Facts and issue: The case examined the applicability of consumer-protection legislation to medical services.

Legal principle: The Court established that medical services falling within the relevant statutory framework can be subject to consumer-protection remedies, with distinctions concerning free services and the particular service arrangement.

Application to artificial organs: A patient who suffers harm from an artificial-organ procedure may have a consumer-law claim where the statutory requirements are satisfied. Depending on the evidence, issues could include defective devices, inadequate warnings, deficient implantation services or failure to provide promised follow-up care.

A successful claim would still require proof of the relevant legal elements.

4. State of Punjab v. Shiv Ram (2005) 7 SCC 1

Court: Supreme Court of India.

Facts and issue: The dispute concerned alleged negligence associated with a medical procedure and the evidentiary burden required to establish liability.

Legal principle: An adverse medical outcome, by itself, does not establish negligence. The claimant must establish the necessary connection between the alleged breach and the injury, subject to the applicable evidentiary principles.

Application to artificial organs: A malfunctioning implant may justify investigation, expert examination and review of clinical records. But the mere fact that an artificial organ ceased functioning does not, without more, establish that its manufacturer or implanting physician was negligent.

5. Indian Society of Organ Transplantation v. Union of India (2025 INSC 1361)

Court: Supreme Court of India, judgment dated 19 November 2025.

Subject: Equality, uniformity and access in organ transplantation.

The judgment discusses the Transplantation of Human Organs Act, 1994 and the legal and administrative arrangements governing organ transplantation. It is relevant to understanding the regulatory background for conventional organ transplantation.

Sci API

+1

Application to artificial organs: The case is useful for distinguishing conventional human-organ transplantation from artificial-organ development. It does not, merely by addressing transplantation governance, establish a dedicated approval regime for mechanical or bioengineered organs.

Case-law summary

7. Liability for artificial-organ failure

Responsibility depends on the cause of the failure, the relevant duty and the applicable legislation.

These are possible grounds of liability, not automatic conclusions. Contractual obligations, statutory provisions, causation, evidence and available defences all matter.

For example, if an artificial heart fails because of a manufacturing defect, the manufacturer may face a different claim from a hospital whose staff ignored repeated alarms. If the failure was an unforeseeable complication despite proper design, manufacture and clinical care, liability may be harder to establish.

8. Ethical issues in artificial-organ development

A. Informed consent and experimental treatment

Patients with end-stage organ failure may be especially vulnerable because conventional treatment options are limited. Regulators and ethics committees should guard against presenting unproven technology as an established cure.

B. Human biological materials

Bioengineered organs may use donor cells, stem cells or human-derived tissues. Developers must address lawful sourcing, consent, traceability, privacy and the applicable rules governing biological materials.

C. Affordability and equality

Advanced artificial organs may initially be available only to wealthy patients or people treated at specialised hospitals. Policymakers must consider whether access criteria are clinically justified and whether public-health programmes can support equitable access.

D. Long-term responsibility

Some implants require batteries, software updates, replacement parts or lifelong monitoring. Patients need clear information about maintenance, device support, manufacturer continuity and the consequences if the manufacturer discontinues the product.

E. Data protection and cybersecurity

An artificial organ connected to external software or a monitoring network may generate sensitive health information. Regulators and manufacturers should address access controls, data minimisation, secure updates and procedures for responding to cyber incidents.

9. Recommendations for a comprehensive regulatory framework

A well-designed artificial-organ regulatory system should include the following measures.

Technology-specific classification: Distinguish mechanical devices, implantable electronic systems, cell-based constructs and hybrid biological devices.

Risk-based authorisation: Require stronger evidence and scrutiny for devices whose failure could cause immediate death or irreversible injury.

Independent clinical oversight: Ensure ethics review, valid consent, appropriate trial registration and participant protection.

Lifecycle surveillance: Maintain implant registries where appropriate, investigate serious adverse events and enable traceable recalls.

Clear liability rules: Establish practical procedures for determining responsibility among manufacturers, hospitals, clinicians and research sponsors.

Transparent regulatory decisions: Require reasoned decisions and suitable review procedures for approval, suspension and withdrawal.

Equitable access: Develop policies for affordability, specialist training and availability beyond major urban hospitals.

Special rules for bioengineered organs: Clarify the treatment of living-cell constructs, engineered tissues and products that combine device and biological functions.

International regulatory practice can inform these measures, but foreign approval should not be assumed to substitute for Indian authorisation where Indian law requires it.

10. Conclusion

Artificial Organ Development Regulation is an emerging intersection of medical-device law, biotechnology, clinical-research ethics, product liability and constitutional protection of health and personal autonomy.

In India, the Medical Devices Rules, 2017 provide an important regulatory foundation for artificial organs that qualify as medical devices. The Transplantation of Human Organs and Tissues Act, 1994 serves a different purpose and does not independently establish a comprehensive regulatory regime for artificial organs. Products involving living human cells or engineered tissues may require additional legal analysis.

The cited judgments supply important principles concerning consent, professional negligence, consumer remedies and transplant governance. They do not establish a single, comprehensive artificial-organ doctrine. The most defensible legal approach is therefore to apply the existing statutes and precedents to the particular technology, while developing clearer rules for bioengineered organs, long-term monitoring, clinical accountability and equitable access.

This is an academic legal overview, not a substitute for advice on a specific device, clinical trial or regulatory application.